Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.48 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.48 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.48 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.48 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.48 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.48 |
| ▸ | GAPDH | P04406 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | STAT6 | P42226 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884759 | 0.90 | EHMT1 (0.48) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL160357 | 0.89 | ADORA3 (0.53) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL9495963 | 0.89 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL6935380 | 0.86 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL28160452 | 0.86 | ADORA3 (0.45) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL5742060 | 0.85 | PI4KA (0.47) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL3488876 | 0.84 | ADORA3 (0.47) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL3317153 | 0.83 | ADORA2A (0.48) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL30716126 | 0.81 | ADORA3 (0.54) | PI4KAPI4K2BPI4K2API4KBADORA3 | |
| SCHEMBL3698843 | 0.81 | ADORA3 (0.54) | PI4KAPI4K2BPI4K2API4KBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2192905-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | Lubin, Adam (US) | 2010-06-09 | — | — | EP | claimed |
| WO-2009032057-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2009-03-12 | — | — | WO | claimed |
| EP-0721347-A1 | AGENT AGAINST SENSITIVE, HYPERREACTIVE AND HYPOACTIVE STATES OF THE SKIN, FORMS OF ACNE, ATOPIC DERMATITIDES, PSORIASIS, PRURIGO, PHOTODERMATOSES, ICHTHYOSIS AND VIRAL INFECTIONS | Beiersdorf Aktiengesellschaft (DE) | 1996-07-17 | — | — | EP | claimed |
| WO-1995005852-A1 | AGENT AGAINST SENSITIVE, HYPERREACTIVE AND HYPOACTIVE STATES OF THE SKIN, FORMS OF ACNE, ATOPIC DERMATITIDES, PSORIASIS, PRURIGO, PHOTODERMATOSES, ICHTHYOSIS AND VIRAL INFECTIONS | BEIERSDORF AG (DE) | 1995-03-02 | — | — | WO | claimed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| CN-109432073-A | Purposes of the MGBG in the drug that preparation treats or prevents progressive MS and its progress | 帕萨罗杰卡有限公司 | 2019-03-08 | — | — | CN | disclosed |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC | 2018-12-20 | — | — | US | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-5952373-A | APPLYING TO THE SKIN AN EFFECTIVE AMOUNT OF ONE OR MORE FLAVONOIDS | BEIERSDORF AG (DE) | 1999-09-14 | — | — | US | disclosed |
| EP-0797427-A1 | AGENTS ACTING AGAINST HYPERREACTIVE AND HYPOACTIVE, DEFICIENT SKIN CONDITIONS AND MANIFEST DERMATITIDES | Beiersdorf Aktiengesellschaft (DE) | 1997-10-01 | — | — | EP | disclosed |
| EP-0721347-A1 | AGENT AGAINST SENSITIVE, HYPERREACTIVE AND HYPOACTIVE STATES OF THE SKIN, FORMS OF ACNE, ATOPIC DERMATITIDES, PSORIASIS, PRURIGO, PHOTODERMATOSES, ICHTHYOSIS AND VIRAL INFECTIONS | Beiersdorf Aktiengesellschaft (DE) | 1996-07-17 | — | — | EP | disclosed |
| WO-1996018381-A1 | AGENTS ACTING AGAINST HYPERREACTIVE AND HYPOACTIVE, DEFICIENT SKIN CONDITIONS AND MANIFEST DERMATITIDES | BEIERSDORF AG (DE) | 1996-06-20 | — | — | WO | disclosed |
| WO-1995005852-A1 | AGENT AGAINST SENSITIVE, HYPERREACTIVE AND HYPOACTIVE STATES OF THE SKIN, FORMS OF ACNE, ATOPIC DERMATITIDES, PSORIASIS, PRURIGO, PHOTODERMATOSES, ICHTHYOSIS AND VIRAL INFECTIONS | BEIERSDORF AG (DE) | 1995-03-02 | — | — | WO | disclosed |
| EP-0233031-B1 | METHYLTHIORIBOSE ANALOGUES, THEIR PREPARATION AND USE AS MEDICINAL AGENTS AND BIOCIDES | STATE OF OREGON BY AND THROUGH OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OREGON HEALTH SC. UNIV. AND OREGON STATE UNIV. (US) | 1993-04-07 | — | — | EP | disclosed |
| US-4820692-A | PARASITICIDES, FUNGICIDES | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND OREGON STATE UNIVERSITY (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0233031-A2 | Methylthioribose analogues, their preparation and use as medicinal agents and biocides | STATE OF OREGON BY AND THROUGH OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OREGON HEALTH SC. UNIV. AND OREGON STATE UNIV. (US) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | SRM, PMP22, SMS | PI4KA 3910/4885PI4K2B 3416/4885PI4K2A 3260/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | PI4KA 4683/4885PI4K2B 3830/4885PI4K2A 4493/4885 |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PMP22, MAG, GMFG | PI4KA 4759/4885PI4K2B 4335/4885PI4K2A 4709/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | PI4KA 4759/4885PI4K2B 4335/4885PI4K2A 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.